Financial Information

These accounts have been produced by chartered accountants and reviewed by our statutory auditor Deloitte & Associates. The following figures (Revenue, 6 312 k€ - Expenses 6 276 k€) do not include provisions.

Revenue 2016
.
Expenses 2016

EURORDIS Expenses 2016

Collapse All
Expand All
Expenses Amount (€) Percentage
Staff 2 647 385 42%
Volunteers 1 113 885 18%
Travel and subsistence 697 905 11%
Services 1 682 567 27%
Purchases 96 300 2%
Miscellaneous 38 125 1%
Sub-total 6 276 167 100%
Contingency and loss provisions 125 434 2%
Total Expenses 6 401 601  
Result -89 417

 

EURORDIS Revenue 2016

Collapse All
Expand All
Revenue Amount (€) Percentage
Patient Organisations 950 467 15%
Individuals 1 126 296 18%
European Commission 1 768 718 28%
National authorities 37 268 1%
Corporates 1 743 574 28%
Not for Profit Organisations 137 780 2%
Event Fees 252 316 4%
Miscellaneous 295 765 5%
Sub-total 6 312 183 100%
Total Revenue 6 312 183  

EURORDIS Corporate Revenue 2016

Collapse All
Expand All

Pharmaceutical & Biotechnology Companies

Company Amount (€) % of Revenue
ACHILLION 10 000 0,16%
ACTELION 45 000 0,71%
AKCEA 10 000 0,16%
ALEXION 20 000 0,32%
ALNYLAM 25 000 0,40%
AMGEN 5 000 0,08%
AMICUS THERAPEUTICS 15 000 0,24%
ARIAD 4 615 0,07%
ASTRAZENECA 10 000 0,16%
AUDENTES 10 000 0,16%
BAXALTA 10 000 0,16%
BAYER 40 000 0,63%
BIOGEN 50 623 0,80%
BIOMARIN 50 000 0,79%
BLUEBIRD BIO 10 000 0,16%
BOEHRINGER INGELHEIM 10 000 0,16%
BRISTOL-MYERS SQUIBB 10 000 0,16%
CELGENE 85 000 1,35%
CHIESI 40 000 0,63%
CLEMENTIA 10 000 0,16%
CSL BEHRING 70 538 1,12%
CYTOKINETICS 30 000 0,48%
DOMPE 5 000 0,08%
EUSA PHARMA 10 000 0,16%
GENZYME 55 000 0,87%
GRIFOLS 10 000 0,16%
GSK 70 000 1,11%
HORIZON 34 000 0,54%
INCYTE 10 000 0,16%
INSMED 5 000 0,08%
INTERCEPT 2 000 0,03%
IPSEN 15 000 0,24%
KYOWA KIRIN 15 000 0,24%
LFB BIOMEDICAMENTS 10 000 0,16%
LYSOGENE 2 000 0,03%
MERCK 10 000 0,16%
NOVARTIS 79 167 1,25%
ORPHAN EUROPE 30 000 0,48%
OVID 5 000 0,08%
PFIZER 107 000 1,70%
PHARMA MAR 5 000 0,08%
PTC 35 000 0,55%
RAPTOR 45 000 0,71%
ROCHE 10 000 0,16%
SANTHERA 15 000 0,24%
SHIRE 120 000 1,90%
SIGMA-TAU 16 615 0,26%
SOBI 30 000 0,48%
SPARK THERAPEUTICS 5 000 0,08%
TAKEDA 37 841 0,60%
UCB 5 000 0,08%
ULTRAGENYX 19 231 0,30%
VANDA 10 000 0,16%
VERTEX 45 000 0,71%
Subtotal Pharmaceutical & Biotechnology Companies 1 443 631 22,87%

Other Health Sector Companies

Company Amount (€) % of Revenue
CYDAN 5 000 0,08%
IDIS-CLINIGEN 15 000 0,24%
MAPI 37 812 0,60%
MARK KRUEGER AND ASSOCIATES 3 000 0,05%
OPENAPP 5 000 0,08%
QUINTILES 25 000 0,40%
Total 90 812 1,44%

Corporates Outside the Health Sector

Company Amount (€) % of Revenue
ARES LIFE SCIENCES 8 000,00 0,13%
BURSON MARSTELLER 3 747,00 0,06%
DLA PIPER 44 781,94 0,71%
GOOGLE 109 185,00 1,73%
INDIVIDUAL VOLUNTEER TRANSLATORS 157,68 0,00%
INTERACTIUS 4 480,00 0,07%
MEDIA PLANET 5 650,15 0,09%
MULTIBURO 10 512,00 0,17%
PUBLICIS LIFEBRAND 11 700,00 0,19%
REDMOND CONSULTING 2 936,35 0,05%
TRANSLATORS WITHOUT BORDERS 2 733,00 0,04%
TROMMONS 5 247,04 0,08%
Total 209 130,16 3,31%

*Cutoff is the of deferred income and brought forward. For example, in the context of a special event, when a donation is made the year before the event, part of the donation is used to cover some of the preparatory costs of the event and the rest is put aside for the following year. » 2016 financial independence form.
» EURORDIS Policy on Financial Support by Commercial Companies  

In addition to the organisations accredited (on the right-hand side), EURORDIS gratefully acknowledges the generous support of the following contributors in 2016:

Health Sector Corporates

Diversification of funding is a key success factor to minimise potential conflict of interest with donors. EURORDIS has diversified its pharmaceutical and biotechnology sector companies’ sponsorship from 51 to 53 different companies in 2016. 6 health sector companies also contributed to the 2016 incomes. Companies have supported EURORDIS through the EURORDIS Round Table of Companies, the European Conference on Rare Diseases Edinburgh 2016, the Multi-Stakeholder Symposium, the EURORDIS Black Pearl Evening, as well as international initiatives such as Rare Barometer, RareConnect™ and Rare Diseases International. The breakdown of each company’s donations by project is detailed on the EURORDIS website on the “Corporate revenue” tab of the “Financial Information” section.

Top five donors

1.Shire
2.Pfizer
3.Celgene
4.Novartis
5. CLS Behring
5.GlaxoSmithKline

Other Pharmaceutical Companies & Health Sector Corporates

Achillion Actelion Akari Akcea Alexion Alnylam AMGEN Amicus Therapeutics AstraZeneca Bayer Schering Pharma AG Bayer Schering Pharma AG Bayer Schering Pharma AG Biogen Idec Biomarin BlueBird Bio boehringer-ingelheimBMS Chiesi Clementia Clinigen Cydan Cytokinetics Dompe Farmaceutici Grifols Horizon Pharma USA Incyte Helsinn Ipsen Jazz pharmaceuticals Kyowa Kirin Leadiant LFB Lysogene-Q MAPI MK&A MSD OpenApp Orphan Europe OVID Pharmamar PTC Therapeutics QuintilesIMS Raptor Roche Sanofigenzyme Santhera UCB UCB UCB UCB Ultragenyx Vanda Vertex

In-kind contributors

Burson-Marsteller DLA PiperGoogleInter ActiusMedia PlanetPublicis HealthRedmond ConsultingRosetta FoundationTranslators without borders

Other contributors

AIPM Logo

AIPM

Association of International Pharmaceutical Manufacturers

 

ares

ARES

Arès Life Sciences


efpia

EFPIA

European Federation of Pharmaceutical Industries and Associations

EveryLife Foundation

EveryLife Foundation for Rare Diseases


Kindness for Kids

Kindness for Kids

 
 
The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseases, Rare Diseases International is a EURORDIS initiativeRare Disease International Bringing together patients, families and experts to share experiences in a moderated multilanguage forum, RareConnect is a EURORDIS initiative RareConnect An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases